Prevalence of RUNX1 gene alterations in de novo adult acute myeloid leukemia

Table 1 Clinical features of the assessed patients with acute myeloid leukemia

Parameter	Frequency	Percent	Median (IQR)
Sex
Male	47	61
Female	30	39
Age in years			42 (18-82)
< 50	52	67.5
≥ 50	25	32.5
TLC as × 109/L			20 (1-377)
Hb in g/dL			8.2 ± 2.39
Platelets as × 109/L			32 (1-658)
PB blast as %			53 (0-63)
BM blast as %			69 (20-97)
MCN			45.8 ± 2.62
< 46	10	14.5
46	47	68.1
> 46	12	17.4
BM cellularity
Hypocellular	3	3.9
Normocellular	11	14.3
Hypercellular	63	81.8
Hepatomegaly
Absent	57	74
Present	20	26
Splenomegaly
Absent	60	77.9
Present	17	22.1
Lymphadenopathy
Absent	52	67.5
Present	25	32.5
FAB classification
M0	4	5.2
M1	10	13
M2	38	49.4
M4	22	28.6
M5a	2	2.6
M7	1	1.3
t (8; 21)
Absent	70	90.9
Present	7	9.1
inv16
Absent	71	92.2
Present	6	7.8
t (9; 22)
Absent	75	97.4
Present	2	2.6
Genetic risk
High	17	22.1
Intermediate	42	54.5
Low	18	23.4
FLT3-ITD
Wild	69	89.6
Mutant	8	10.4
FLT3-TKD
Wild	75	97.4
Mutant	2	2.6
C-KIT
Wild	76	98.7
Mutant	1	1.3
NPM
Wild	63	81.8
Mutant	14	18.2
BM blast on day 15			0.03 (0-1)
BM cellularity on day 15
Hypocellular	41	68.3
Normocellular	11	18.3
Hypercellular	8	13.3
BM blast on day 28			0.03 (0-1)
BM cellularity on day 28
Hypocellular	6	14.6
Normocellular	21	51.2
Hypercellular	14	34.1
CR
Negative	37	48.1
Positive	40	51.9
Delayed CR
Negative	70	90.9
Positive	7	9.1
Resistance
Negative	67	87
Positive	10	13
Relapse
Negative	63	81.8
Positive	14	18.2
Death
Negative	20	26
Positive	57	74
Early death
Negative	41	53.2
Positive	36	46.8

BM: Bone marrow; CR: Complete remission; FAB: French-American-British; Hb: Hemoglobin; IQR: Interquartile range; MCN: Modal chromosomal number; PB: Peripheral blood; TLC: Total leucocytic count.